PND43 ECONOMIC EVALUATION OF FINGOLIMOD COMPARED TO INTERFERON-β1A IN THE TREATMENT OF PEDIATRIC-ONSET MULTIPLE SCLEROSIS (POMS) IN MEXICO

Abstract

days/year that were previously lost due to migraine, resulting in a positive ROI of 510%. In addition to ROI and work productivity gained, participants also gained on average 13.6 migraine-free days/year for their private and social life. Conclusions: This analysis concludes that the migraine disease management program has a high ROI informing other employers that the systematic inclusion of migraine management into corporate health management programs can be of significant benefit to the impacted individuals as well as the companies.